Article info

PDF

Extended report
Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs

Authors

  1. Correspondence to Dr Anja Strangfeld, Deutsches Rheuma-Forschungszentrum Berlin, Ein Leibniz Institut, Programmbereich Epidemiologie, Charitéplatz 1, Berlin 10117, Germany; strangfeld{at}drfz.de
View Full Text

Citation

Strangfeld A, Richter A, Siegmund B, et al
Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs

Publication history

  • Received April 22, 2016
  • Revised May 20, 2016
  • Accepted June 19, 2016
  • First published July 12, 2016.
Online issue publication 
February 17, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.